Medicare Drug Pricing Casts A Cloud Over J.P. Morgan’s Opening Day
Executive Summary
Inflation Reduction Act means that industry ‘will have to adjust’ to new market realities, especially for small molecule drugs.
You may also be interested in...
The IRA And US FDA: How Will Agency View Any Drug Development Changes?
US biopharma companies are warning of significant changes in drug development priorities as they prepare for the implementation of new Medicare pricing measures enacted in 2022. Those changes will have ripple effects on the FDA, which may spark some responses.
J.P. Morgan Day Four: Talking With Execs About BD Plans
Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.
IRA Already Impacting Merck & Co. BD Decisions, CEO Davis Says
Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.